ALSPW.PA WACC - Weighted Average Cost of Capital
The WACC of Spineway SA (ALSPW.PA) is 4.0%.
| Range | Selected | |
| Cost of equity | 7.7% - 16.0% | 11.85% |
| Tax rate | 25.9% - 27.1% | 26.5% |
| Cost of debt | 5.0% - 5.0% | 5% |
| WACC | 3.9% - 4.1% | 4.0% |
| Category | Low | High |
| Long-term bond rate | 3.0% | 3.5% |
| Equity market risk premium | 5.8% | 6.8% |
| Adjusted beta | 0.82 | 1.77 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 7.7% | 16.0% |
| Tax rate | 25.9% | 27.1% |
| Debt/Equity ratio | 24.99 | 24.99 |
| Cost of debt | 5.0% | 5.0% |
| After-tax WACC | 3.9% | 4.1% |
| Selected WACC | 4.0% | |
| Debt/Equity | Unlevered | |||
| Peers | Company Name | ratio | Beta | beta |
| ALSPW.PA | Spineway SA | 24.99 | 0.2 | 0.01 |
| ACARIX.ST | Acarix AB | 1.18 | -0.78 | -0.42 |
| ALBIO.PA | Biosynex SA | 2.83 | 0.07 | 0.02 |
| ALBLU.PA | Bluelinea SA | 0.46 | 0.89 | 0.67 |
| ALIMP.PA | Implanet SA | 0.5 | 0.31 | 0.22 |
| ALTHE.PA | Theraclion SA | 0.14 | 1 | 0.9 |
| BIOBV.HE | Biohit Oyj | 0.01 | 0.19 | 0.19 |
| PHLOG B.ST | Pharmacolog I Uppsala AB (publ) | 0.06 | 0.05 | 0.05 |
| PLUN.ST | ProstaLund AB | 0.12 | 0.07 | 0.06 |
| SCIB.ST | SciBase Holding AB (publ) | 0.88 | -0.48 | -0.29 |
| Low | High | |
| Unlevered beta | 0.04 | 0.11 |
| Relevered beta | 0.73 | 2.15 |
| Adjusted relevered beta | 0.82 | 1.77 |
ALSPW.PA's CAPM model and how its cost of Equity is calculated
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for ALSPW.PA:
cost_of_equity (11.85%) = risk_free_rate (3.25%) + equity_risk_premium (6.30%) * adjusted_beta (0.82) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.